Publications by Pål Andre Holme

110 publications found

Publications 2024

  1. Holme PA, Poulsen LH, Tueckmantel C, Maas Enriquez M, Alvarez Román MT, De Cristofaro R (2024)
    Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study
    Haemophilia, 30 (2), 388-394
    DOI 10.1111/hae.14930, PubMed 38229269
  2. Reding MT, Simpson M, Ducore J, Holme PA, Maas Enriquez M, Mancuso ME (2024)
    Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII
    Acta Haematol, 1-10 (in press)
    DOI 10.1159/000538702, PubMed 38599195

Publications 2023

  1. Arvanitakis A, Holme PA, Berntorp E, Astermark J (2023)
    Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
    Haemophilia, 29 (4), 1032-1038
    DOI 10.1111/hae.14806, PubMed 37252898
  2. Astermark J, Baghaei F, Strandberg K, Toplican PG, Birkedal MF, Grahn EE, Hansson C, Kampmann P, Lehtinen AE, Täckström K, Holme PA, Magnusson M (2023)
    Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
    Ther Adv Hematol, 14, 20406207231202306
    DOI 10.1177/20406207231202306, PubMed 37859645
  3. Ettingshausen CE, Hermans C, Holme PA, Cid AR, Khair K, Oldenburg J, Négrier C, Botha J, Lelli A, Windyga J (2023)
    Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
    Ther Adv Hematol, 14, 20406207231184323
    DOI 10.1177/20406207231184323, PubMed 37529276
  4. Hermans C, Astermark J, Carvalho M, Dolan G, d'Oiron R, Fontana P, Holme PA, Kenet G, Klamroth R, Mancuso ME, Marquardt N, Nunez R, Katsarou O, Pabinger-Fasching I, Quintavalle G, Rodgers R, van der Valk P, Windyga J, Jimenez Yuste V, Preložnik Zupan I (2023)
    Prevalence of COVID-19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from Europe
    Haemophilia, 29 (3), 913-916
    DOI 10.1111/hae.14761, PubMed 36802089
  5. Hillarp A, Holme PA, Wåland EP, Le MS, Henriksson CE, Tjønnfjord GE, Måseide RJ (2023)
    Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII
    J Thromb Haemost, 21 (10), 2771-2775
    DOI 10.1016/j.jtha.2023.07.019, PubMed 37543216
  6. Jørgensen OJ, Steineger JE, Hillarp A, Pareli Wåland E, Holme PA, Heimdal K, Dheyauldeen S (2023)
    Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
    Laryngoscope Investig Otolaryngol, 9 (1), e1196
    DOI 10.1002/lio2.1196, PubMed 38362186
  7. Matlary RED, Grydeland M, Glosli H, Rueegg CS, Holme PA (2023)
    Physical activity in Norwegian teenagers and young adults with haemophilia A compared to general population peers
    Haemophilia, 29 (2), 658-667
    DOI 10.1111/hae.14752, PubMed 36723510
  8. Matlary RED, Grydeland M, Glosli H, Rueegg CS, Holme PA (2023)
    Factors associated with physical activity in young people with haemophilia A on prophylaxis
    Haemophilia, 29 (3), 900-909
    DOI 10.1111/hae.14776, PubMed 36913380
  9. Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Tjønnfjord GE, Holme PA (2023)
    Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
    Haemophilia, 30 (1), 98-105
    DOI 10.1111/hae.14899, PubMed 37983883
  10. Reding MT, Pabinger I, Holme PA, Maas Enriquez M, Mancuso ME, Lalezari S, Miesbach W, Di Minno G, Klamroth R, Hermans C (2023)
    Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
    Ther Adv Hematol, 14, 20406207231166779
    DOI 10.1177/20406207231166779, PubMed 37113811
  11. Warlo EMK, Kalstad AA, Myhre PL, Solheim S, Arnesen H, Tveit A, Holme PA, Seljeflot I, Bratseth V (2023)
    von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
    Res Pract Thromb Haemost, 7 (4), 100164
    DOI 10.1016/j.rpth.2023.100164, PubMed 37255854

Publications 2022

  1. Arvanitakis A, Holme PA, Berntorp E, Astermark J (2022)
    Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973
    Haemophilia, 28 (2), 223-229
    DOI 10.1111/hae.14489, PubMed 35005818
  2. Hetland G, Fagerhol MK, Wiedmann MKH, Søraas AVL, Mirlashari MR, Nissen-Meyer LSH, Istre MS, Holme PA, Schultz NH (2022)
    Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects
    Vaccines (Basel), 10 (8)
    DOI 10.3390/vaccines10081267, PubMed 36016155
  3. Kihlberg K, Baghaei F, Bruzelius M, Funding E, Holme PA, Lassila R, Martin M, Nummi V, Ranta S, Strandberg K, Andersson NG, Berntorp E, Astermark J (2022)
    Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
    Thromb Res, 217, 22-32
    DOI 10.1016/j.thromres.2022.06.015, PubMed 35842956
  4. Klamroth R, Ay C, De Moerloose P, Fontana P, Windyga J, Astermark J, Berntorp E, Carvalho M, Dolan G, Hermans C, Holme PA, Kenet G, Mancuso ME, Marquardt N, Nunez R, Pabinger I, Rodgers R, Valk PV, Yuste VJ, Zupan IP (2022)
    Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working Group
    Haemophilia, 29 (1), 21-32
    DOI 10.1111/hae.14674, PubMed 36271497
  5. Klintman J, Akesson KE, Holme PA, Fischer K (2022)
    Bone mineral density in haemophilia - a multicentre study evaluating the impact of different replacement regimens
    Haemophilia, 28 (2), 239-246
    DOI 10.1111/hae.14487, PubMed 34994489
  6. Lehtinen AE, Baghaei F, Astermark J, Holme PA (2022)
    Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries
    Haemophilia, 28 (5), 713-719
    DOI 10.1111/hae.14585, PubMed 35575446
  7. Matlary RED, Holme PA, Glosli H, Rueegg CS, Grydeland M (2022)
    Comparison of free-living physical activity measurements between ActiGraph GT3X-BT and Fitbit Charge 3 in young people with haemophilia
    Haemophilia, 28 (6), e172-e180
    DOI 10.1111/hae.14624, PubMed 35830613
  8. Schultz NH, Søraas AVL, Sørvoll IH, Akkök ÇA, Vetlesen A, Bhamra JS, Ahlen MT, Holme PA, Aamodt AH, Skagen K, Skattør TH, Skjelland M, Wiedmann MK (2022)
    Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study
    J Stroke Cerebrovasc Dis, 32 (1), 106860
    DOI 10.1016/j.jstrokecerebrovasdis.2022.106860, PubMed 36403363
  9. Szanto T, Zetterberg E, Ramström S, Leinøe EB, Holme PA, Antovic JP, Holmström M, Onundarson PT, Pikta M, Vaide I, Olsson A, Magnusson M, Kärkkäinen S, Bitar M, Poulsen LH, Lassila R, Nordic Haemophilia Council (2022)
    Platelet function testing: Current practice among clinical centres in Northern Europe
    Haemophilia, 28 (4), 642-648
    DOI 10.1111/hae.14578, PubMed 35510959
  10. Ueland T, Hausberg I, Mørtberg TV, Dahl TB, Lerum TV, Michelsen A, Ranheim T, Nezvalova Henriksen K, Dyrhol-Riise AM, Holme PA, Aaløkken TM, Skjønsberg OH, Barratt-Due A, Ahlén MT, Aukrust P, Halvorsen B (2022)
    Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology
    Platelets, 33 (4), 640-644
    DOI 10.1080/09537104.2022.2042238, PubMed 35225150
  11. Warlo EMK, Bratseth V, Pettersen AR, Holme PA, Arnesen H, Seljeflot I, Opstad TB (2022)
    Genetic Variation in ADAMTS13 is Related to VWF Levels, Atrial Fibrillation and Cerebral Ischemic Events
    Clin Appl Thromb Hemost, 28, 10760296221141893
    DOI 10.1177/10760296221141893, PubMed 36474435

Publications 2021

  1. Astermark J, Ay C, Carvalho M, D'Oiron R, Moerloose P, Dolan G, Fontana P, Hermans C, Holme PA, Katsarou O, Kenet G, Klamroth R, Mancuso ME, Marquardt N, Núñez R, Pabinger I, Tait R, Valk PV (2021)
    New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
    Thromb Haemost, 122 (6), 905-912
    DOI 10.1055/a-1642-4067, PubMed 34507368
  2. Holm S, Kared H, Michelsen AE, Kong XY, Dahl TB, Schultz NH, Nyman TA, Fladeby C, Seljeflot I, Ueland T, Stensland M, Mjaaland S, Goll GL, Nissen-Meyer LS, Aukrust P, Skagen K, Gregersen I, Skjelland M, Holme PA, Munthe LA, Halvorsen B (2021)
    Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
    Eur Heart J, 42 (39), 4064-4072
    DOI 10.1093/eurheartj/ehab506, PubMed 34405870
  3. Holstein K, Le Quellec S, Klamroth R, Batorova A, Holme PA, Jiménez-Yuste V, Astermark J (2021)
    Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
    Haemophilia, 28 (2), 215-222
    DOI 10.1111/hae.14470, PubMed 34918839
  4. Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA (2021)
    Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
    Haemophilia, 27 (4), 519-530
    DOI 10.1111/hae.14322, PubMed 33988293
  5. Johansen S, Laegreid IJ, Ernstsen SL, Azrakhsh NA, Kittang AO, Lindås R, Gjertsen BT, Vetti N, Mørtberg TV, Sørvoll IH, Holme PA, Ahlen MT, Reikvam H (2021)
    Thrombosis and thrombocytopenia after HPV vaccination
    J Thromb Haemost, 20 (3), 700-704
    DOI 10.1111/jth.15604, PubMed 34817130
  6. Måseide RJ, Berntorp E, Astermark J, Hansen J, Olsson A, Bruzelius M, Frisk T, Aspdahl M, Nummi V, Tjønnfjord GE, Holme PA (2021)
    Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
    Haemophilia, 27 (2), e253-e259
    DOI 10.1111/hae.14245, PubMed 33550602
  7. Måseide RJ, Berntorp E, Nummi V, Lassila R, Tjønnfjord GE, Holme PA (2021)
    Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation
    Haemophilia, 27 (5), 793-801
    DOI 10.1111/hae.14355, PubMed 34106506
  8. Reding MT, Pabinger I, Holme PA, Poulsen L, Negrier C, Chalasani P, Maas Enriquez M, Wang M, Meijer K, Mancuso ME, Lalezari S (2021)
    Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study
    Haemophilia, 27 (3), e347-e356
    DOI 10.1111/hae.14297, PubMed 33818853
  9. Schultz NH, Fareed J, Holme PA (2021)
    Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study
    Clin Appl Thromb Hemost, 27, 10760296211021156
    DOI 10.1177/10760296211021156, PubMed 34060371
  10. Schultz NH, Glosli H, Bjørnsen S, Holme PA (2021)
    The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study
    Res Pract Thromb Haemost, 5 (5), e12561
    DOI 10.1002/rth2.12561, PubMed 34263107
  11. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA (2021)
    Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
    N Engl J Med, 384 (22), 2124-2130
    DOI 10.1056/NEJMoa2104882, PubMed 33835768
  12. Wiedmann M, Skattør T, Stray-Pedersen A, Romundstad L, Antal EA, Marthinsen PB, Sørvoll IH, Leiknes Ernstsen S, Lund CG, Holme PA, Johansen TO, Brunborg C, Aamodt AH, Schultz NH, Skagen K, Skjelland M (2021)
    Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series
    Front Neurol, 12, 721146
    DOI 10.3389/fneur.2021.721146, PubMed 34393988

Publications 2020

  1. Gorkom BL, Holme PA, Joch C, Rogosch T, Feussner A, McKeand W, Roberts J, van Heerde W (2020)
    Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency
    Hematology, 25 (1), 17-25
    DOI 10.1080/16078454.2019.1700329, PubMed 31852380
  2. Kempton CL, Makris M, Holme PA (2020)
    Management of comorbidities in haemophilia
    Haemophilia, 27 Suppl 3, 37-45
    DOI 10.1111/hae.14013, PubMed 32476243
  3. Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Tjønnfjord GE, Holme PA (2020)
    Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B - The MoHem study
    Haemophilia, 26 (5), 891-897
    DOI 10.1111/hae.14114, PubMed 33021747
  4. Qvigstad C, Sørensen LQ, Tait RC, de Moerloose P, Holme PA, ADVANCE Working Group (2020)
    Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension
    Medicine (Baltimore), 99 (9), e19339
    DOI 10.1097/MD.0000000000019339, PubMed 32118768
  5. Qvigstad C, Tait RC, de Moerloose P, Holme PA, ADVANCE Working Group (2020)
    Hematuria in aging men with hemophilia: Association with factor prophylaxis
    Res Pract Thromb Haemost, 4 (2), 309-317
    DOI 10.1002/rth2.12298, PubMed 32110762
  6. Tjønnfjord E, Holme PA, Darne B, Khelif A, Waage A, Michel M, Ben Romdhan N, Ghanima W (2020)
    Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study
    Br J Haematol, 191 (3), 460-465
    DOI 10.1111/bjh.16672, PubMed 32342497

Publications 2019

  1. Andersen MF, Holme PA, Tjønnfjord GE (2019)
    [Surgical procedures in patients with severe haemophilia 1997–2014]
    Tidsskr Nor Laegeforen, 139 (8)
    DOI 10.4045/tidsskr.18.0592, PubMed 31062561
  2. Andersen MLF, Holme PA, Tjonnfjord GE (2019)
    Surgical intervention in patients with severe bleeding disorder 1997-2014
    Tidsskr. Nor. Laegeforen., 139 (8), 709-712
  3. Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E (2019)
    Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A
    Res Pract Thromb Haemost, 3 (3), 542-554
    DOI 10.1002/rth2.12220, PubMed 31294338
  4. Lalezari S, Reding MT, Pabinger I, Holme PA, Negrier C, Chalasani P, Shin HJ, Wang M, Tseneklidou-Stoeter D, Maas Enriquez M (2019)
    BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
    Haemophilia, 25 (6), 1011-1019
    DOI 10.1111/hae.13853, PubMed 31621991
  5. Ljungkvist M, Strandberg K, Berntorp E, Chaireti R, Holme PA, Larsen OH, Lassila R, Jouppila A, Szanto T, Zetterberg E (2019)
    Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: A Nordic study
    Haemophilia, 25 (2), 334-342
    DOI 10.1111/hae.13640, PubMed 30715788
  6. Schultz NH, Holme PA, Henriksson CE, Mowinckel MC, Sandset PM, Bratseth V, Jacobsen EM (2019)
    The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
    Thromb Res, 177, 154-156
    DOI 10.1016/j.thromres.2019.03.010, PubMed 30903875

Publications 2018

  1. Gamage TH, Gunnes G, Lee RH, Louch WE, Holmgren A, Bruton JD, Lengle E, Kolstad TRS, Revold T, Amundsen SS, Dalen KT, Holme PA, Tjønnfjord GE, Christensen G, Westerblad H, Klungland A, Bergmeier W, Misceo D, Frengen E (2018)
    STIM1 R304W causes muscle degeneration and impaired platelet activation in mice
    Cell Calcium, 76, 87-100
    DOI 10.1016/j.ceca.2018.10.001, PubMed 30390422
  2. Holme PA, Tjønnfjord GE (2018)
    Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries
    Haemophilia, 25 (1), 54-59
    DOI 10.1111/hae.13625, PubMed 30394617
  3. Qvigstad C, Tait RC, Rauchensteiner S, Berntorp E, de Moerloose P, Schutgens RE, Holme PA, ADVANCE Working Group (2018)
    The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
    Medicine (Baltimore), 97 (39), e12551
    DOI 10.1097/MD.0000000000012551, PubMed 30278553
  4. Schultz NH, Holme PA, Bjørnsen S, Henriksson CE, Sandset PM, Jacobsen EM (2018)
    The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis
    Platelets, 31 (1), 43-47
    DOI 10.1080/09537104.2018.1557618, PubMed 30569801
  5. Schultz NH, Lundblad R, Holme PA (2018)
    Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
    J Med Case Rep, 12 (1), 138
    DOI 10.1186/s13256-018-1660-9, PubMed 29764497

Publications 2017

  1. Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D, van den Berg M, Blatný J, Chambost H, Doria AS, Holme PA, Kaczmarek R, Mantovani L, McLaughlin P, Nanayakkara L, Petrini P, Sannié T, Laane E, Maia R, Dettoraki A, Farrell A, Halimeh S, Raza S et al. (2017)
    The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
    Eur J Haematol, 98 Suppl 85, 1-15
    DOI 10.1111/ejh.12828, PubMed 28101938
  2. Holme PA, Tjønnfjord GE, Batorova A (2017)
    Continuous infusion of coagulation factor concentrates during intensive treatment
    Haemophilia, 24 (1), 24-32
    DOI 10.1111/hae.13331, PubMed 28873263
  3. Osooli M, Steen Carlsson K, Baghaei F, Holmström M, Rauchensteiner S, Holme PA, Hvitfeldt L, Astermark J, Berntorp E (2017)
    The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register
    Haemophilia, 23 (3), e180-e187
    DOI 10.1111/hae.13231, PubMed 28393468
  4. Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
    The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
    Thromb J, 15, 6
    DOI 10.1186/s12959-017-0129-1, PubMed 28239301
  5. Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
    The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro
    Res Pract Thromb Haemost, 1 (1), 49-56
    DOI 10.1002/rth2.12015, PubMed 30046673

Publications 2016

  1. Barratt-Due A, Fløisand Y, Orrem HL, Kvam AK, Holme PA, Bergseth G, Tjønnfjord GE, Mollnes TE (2016)
    Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome
    Rheumatology (Oxford), 55 (7), 1337-9
    DOI 10.1093/rheumatology/kew040, PubMed 27105662
  2. Berger K, Schopohl D, Lowe G, Holme PA, Tait RC, Combescure C, Rauchensteiner S, Klamroth R (2016)
    How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population
    Haemophilia, 22 (5), e406-16
    DOI 10.1111/hae.13069, PubMed 27650262
  3. Haig Y, Enden T, Grøtta O, Kløw NE, Slagsvold CE, Ghanima W, Sandvik L, Hafsahl G, Holme PA, Holmen LO, Njaaastad AM, Sandbæk G, Sandset PM, CaVenT Study Group (2016)
    Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial
    Lancet Haematol, 3 (2), e64-71
    DOI 10.1016/S2352-3026(15)00248-3, PubMed 26853645
  4. James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P, Global Emerging HEmostasis Experts Panel (GEHEP) (2016)
    Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study
    Haemophilia, 22 (6), 912-918
    DOI 10.1111/hae.13089, PubMed 27868369

Publications 2015

  1. Fogarty PF, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme PA, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A, Global Emerging Hemophilia Panel (GEHEP) (2015)
    Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey
    Haemophilia, 21 (5), 589-97
    DOI 10.1111/hae.12652, PubMed 25689278
  2. Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, RITP study group (2015)
    Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
    Lancet, 385 (9978), 1653-61
    DOI 10.1016/S0140-6736(14)61495-1, PubMed 25662413
  3. Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P, ADVANCE Working Group (2015)
    Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe
    Haemophilia, 22 (2), 248-255
    DOI 10.1111/hae.12847, PubMed 27880029
  4. Valentino LA, Holme PA (2015)
    Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?
    Haemophilia, 21 (6), 709-14
    DOI 10.1111/hae.12723, PubMed 26036756

Publications 2014

  1. Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
    [Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
    Tidsskr Nor Laegeforen, 134 (16), 1569-75
    DOI 10.4045/tidsskr.13.1415, PubMed 25178233
  2. Kristiansen A, Brandt L, Agoritsas T, Akl EA, Berge E, Bondi J, Dahm AE, Granan LP, Halvorsen S, Holme PA, Flem Jacobsen A, Jacobsen EM, Neumann I, Sandset PM, Sætre T, Tveit A, Vartdal T, Guyatt G, Vandvik PO (2014)
    Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process
    Chest, 146 (3), 727-734
    DOI 10.1378/chest.13-2828, PubMed 25180723
  3. Misceo D, Holmgren A, Louch WE, Holme PA, Mizobuchi M, Morales RJ, De Paula AM, Stray-Pedersen A, Lyle R, Dalhus B, Christensen G, Stormorken H, Tjønnfjord GE, Frengen E (2014)
    A dominant STIM1 mutation causes Stormorken syndrome
    Hum Mutat, 35 (5), 556-64
    DOI 10.1002/humu.22544, PubMed 24619930
  4. Tran HTT, Sørensen B, Bjørnsen S, Pripp AH, Tjønnfjord GE, Andre Holme P (2014)
    Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay
    Haemophilia, 21 (2), 275-283
    DOI 10.1111/hae.12570, PubMed 25521720
  5. Tvedt TH, Holme PA, Bruserud Ø (2014)
    [A man in his 80s with muscle stiffness and skin bleeding]
    Tidsskr Nor Laegeforen, 134 (10), 1058-61
    DOI 10.4045/tidsskr.13.0817, PubMed 24865732
  6. Vandvik PO, Granan LP, Holme PA, Bondi J (2014)
    [Antithrombotic therapy in surgery]
    Tidsskr Nor Laegeforen, 134 (9), 925
    DOI 10.4045/tidsskr.13.1580, PubMed 24828716

Publications 2013

  1. Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, Peyvandi F, van Heerde WL (2013)
    Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect
    Thromb Res, 132 (2), 256-62
    DOI 10.1016/j.thromres.2013.05.027, PubMed 23834817
  2. Tran HT, Sørensen B, Rea CJ, Bjørnsen S, Ueland T, Pripp AH, Tjønnfjord GE, Holme PA (2013)
    Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors
    Haemophilia, 20 (3), 369-75
    DOI 10.1111/hae.12318, PubMed 24251535
  3. Tran HT, Tjønnfjord GE, Holme PA (2013)
    Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency
    Haemophilia, 20 (1), 141-6
    DOI 10.1111/hae.12256, PubMed 23992369
  4. van Geffen M, Mathijssen NC, Holme PA, Laros-van Gorkom BA, van Kraaij MG, Masereeuw R, Peyvandi F, van Heerde WL (2013)
    Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients
    Thromb Res, 132 (1), 116-22
    DOI 10.1016/j.thromres.2013.04.021, PubMed 23731565
  5. Westberg M, Paus AC, Holme PA, Tjønnfjord GE (2013)
    Haemophilic arthropathy: long-term outcomes in 107 primary total knee arthroplasties
    Knee, 21 (1), 147-50
    DOI 10.1016/j.knee.2013.09.010, PubMed 24156923

Publications 2012

  1. Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, Lopez-Fernández M, Fijnvandraat K, European Haemophilia Treatment Standardisation Board (2012)
    Continuous infusion in haemophilia: current practice in Europe
    Haemophilia, 18 (5), 753-9
    DOI 10.1111/j.1365-2516.2012.02810.x, PubMed 22530687
  2. Holmström M, Tran HT, Holme PA (2012)
    Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience
    Haemophilia, 18 (4), 544-9
    DOI 10.1111/j.1365-2516.2012.02748.x, PubMed 22348384

Publications 2011

  1. Enden T, Haig Y, Kløw NE, Slagsvold CE, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM, CaVenT Study Group (2011)
    Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial
    Lancet, 379 (9810), 31-8
    DOI 10.1016/S0140-6736(11)61753-4, PubMed 22172244
  2. Ghanima W, Kleven IW, Enden T, Rosales A, Wik HS, Pederstad L, Holme PA, Sandset PM (2011)
    Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis
    J Thromb Haemost, 9 (6), 1261-3
    DOI 10.1111/j.1538-7836.2011.04298.x, PubMed 21489133
  3. Lassila R, Holme PA, Landorph A, Petrini P, Onundarson PT, Hillarp A (2011)
    Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease
    Semin Thromb Hemost, 37 (5), 495-502
    DOI 10.1055/s-0031-1281034, PubMed 22102192
  4. Tran HT, Tjønnfjord GE, Paus A, Holme PA (2011)
    rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency
    Haemophilia, 17 (5), 764-70
    DOI 10.1111/j.1365-2516.2011.02596.x, PubMed 21707871
  5. Vetlesen A, Holme PA, Lyberg T, Kjeldsen-Kragh J (2011)
    Recovery, survival, and function of transfused platelets and detection of platelet engraftment after allogeneic stem cell transplantation
    Transfusion, 52 (6), 1321-32
    DOI 10.1111/j.1537-2995.2011.03442.x, PubMed 22084943

Publications 2010

  1. Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K, European Haemophilia Therapy Standardisation Board (2010)
    Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
    Haemophilia, 16 (5), 747-66
    DOI 10.1111/j.1365-2516.2010.02231.x, PubMed 20398077
  2. Ghanima W, Holme PA, Tjønnfjord GE (2010)
    [Immune thrombocytopenia--pathophysiology and treatment]
    Tidsskr Nor Laegeforen, 130 (21), 2120-3
    DOI 10.4045/tidsskr.09.1119, PubMed 21052113

Publications 2009

  1. Astermark J, Negrier C, Hermans C, Holme PA, Klamroth R, Kotsi P, de Moerloose P, Pasi J, Rocino A, von Depka M, Windyga J, Ludlam CA, Interdisciplinary Working Group IDWG (2009)
    European curriculum for thrombosis and haemostasis
    Haemophilia, 15 (1), 337-44
    DOI 10.1111/j.1365-2516.2008.01836.x, PubMed 19149857
  2. Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM, CaVenT study group (2009)
    Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency
    J Thromb Haemost, 7 (8), 1268-75
    DOI 10.1111/j.1538-7836.2009.03464.x, PubMed 19422443
  3. Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE (2009)
    Home treatment with bypassing products in inhibitor patients: a 7.5-year experience
    Haemophilia, 15 (3), 727-32
    DOI 10.1111/j.1365-2516.2009.02017.x, PubMed 19320748
  4. Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M, Lassila R, Mumford A, Pasi J, Wilde J, Will A, Yee TT (2009)
    FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
    Haemophilia, 16 (1), 80-9
    DOI 10.1111/j.1365-2516.2009.02104.x, PubMed 19780845
  5. Vik A, Holme PA, Singh K, Dorenberg E, Nordhus KC, Kumar S, Hansen JB (2009)
    Catheter-directed thrombolysis for treatment of deep venous thrombosis in the upper extremities
    Cardiovasc Intervent Radiol, 32 (5), 980-7
    DOI 10.1007/s00270-009-9655-y, PubMed 19641959

Publications 2008

  1. Brinch L, Tjønnfjord G, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I (2008)
    [Allogeneic stem cell transplantation in acute myelogenous leukemia]
    Tidsskr Nor Laegeforen, 128 (15), 1681-2; author reply 1682
    PubMed 18704137
  2. Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE (2008)
    [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]
    Tidsskr Nor Laegeforen, 128 (22), 2563-6
    PubMed 19023351
  3. Holme PA, Michelsen AE (2008)
    [A 40-year old woman with dizziness and vomiting]
    Tidsskr Nor Laegeforen, 128 (12), 1413-5
    PubMed 18584769
  4. Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM (2008)
    Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
    Thromb Haemost, 99 (6), 1040-8
    DOI 10.1160/TH07-09-0541, PubMed 18521506

Publications 2007

  1. Enden T, Sandvik L, Kløw NE, Hafsahl G, Holme PA, Holmen LO, Ghanima W, Njaastad AM, Sandbaek G, Slagsvold CE, Sandset PM (2007)
    Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771)
    Am Heart J, 154 (5), 808-14
    DOI 10.1016/j.ahj.2007.07.010, PubMed 17967583
  2. Holme PA (2007)
    [Deficient thrombosis prophylaxis]
    Tidsskr Nor Laegeforen, 127 (9), 1176
    PubMed 17479132
  3. Tjønnfjord GE, Holme PA (2007)
    Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
    Vasc Health Risk Manag, 3 (4), 527-31
    PubMed 17969383

Publications 2005

  1. Holme PA, Brosstad F, Tjønnfjord GE (2005)
    Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies
    Haemophilia, 11 (5), 510-5
    DOI 10.1111/j.1365-2516.2005.01136.x, PubMed 16128896

Publications 1998

  1. Holme PA, Müller F, Solum NO, Brosstad F, Frøland SS, Aukrust P (1998)
    Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection
    FASEB J, 12 (1), 79-89
    DOI 10.1096/fasebj.12.1.79, PubMed 9438413
  2. Holme PA, Solum NO, Brosstad F, Pedersen T, Kveine M (1998)
    Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregate with platelets
    Thromb Haemost, 79 (2), 389-94
    PubMed 9493596
  3. Sakariassen KS, Holme PA, Orvim U, Barstad RM, Solum NO, Brosstad FR (1998)
    Shear-induced platelet activation and platelet microparticle formation in native human blood
    Thromb Res, 92 (6 Suppl 2), S33-41
    DOI 10.1016/s0049-3848(98)00158-3, PubMed 9886908

Publications 1997

  1. Holme PA, Orvim U, Hamers MJ, Solum NO, Brosstad FR, Barstad RM, Sakariassen KS (1997)
    Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis
    Arterioscler Thromb Vasc Biol, 17 (4), 646-53
    DOI 10.1161/01.atv.17.4.646, PubMed 9108776

Publications 1996

  1. Holme PA, Røsger M, Solum NO, Brosstad F, Larsen AM, Hovig T (1996)
    Glycoprotein IIb-IIIa on platelet-derived microparticles, and microparticle structures studied by electron microscopy, confocal laser microscopy and crossed radio-immunoelectrophoresis
    Platelets, 7 (4), 207-14
    DOI 10.3109/09537109609023580, PubMed 21043689

Publications 1995

  1. Holme PA, Brosstad F, Solum NO (1995)
    Platelet-derived microvesicles and activated platelets express factor Xa activity
    Blood Coagul Fibrinolysis, 6 (4), 302-10
    DOI 10.1097/00001721-199506000-00002, PubMed 7548677
  2. Holme PA, Solum NO, Brosstad F, Egberg N, Lindahl TL (1995)
    Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa
    Thromb Haemost, 74 (6), 1533-40
    PubMed 8772233
  3. Røger M, Høgåsen K, Holme PA, Halstensen TS, Mollnes TE, Hovig T (1995)
    The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood Platelets Inhibiting Platelet Aggregation
    Platelets, 6 (3), 160-8
    DOI 10.3109/09537109509013269, PubMed 21043620
  4. Solum NO, Holme PA, Pedersen TM (1995)
    Detection of biotinylated proteins in crossed immunoelectrophoresis gels: studies on platelet membrane receptors and microparticles
    Electrophoresis, 16 (8), 1408-13
    DOI 10.1002/elps.11501601233, PubMed 8529606

Publications 1994

  1. Holme PA, Solum NO, Brosstad F, Røger M, Abdelnoor M (1994)
    Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and western blotting
    Thromb Haemost, 72 (5), 666-71
    PubMed 7900071

Publications 1993

  1. Holme PA, Brosstad F, Solum NO (1993)
    The difference between platelet and plasma FXIII used to study the mechanism of platelet microvesicle formation
    Thromb Haemost, 70 (4), 681-6
    PubMed 8115996

Page visits: 3832